Irofulven

Drug Profile

Irofulven

Alternative Names: 6-HMAF; 6-hydroxymethylacylfulvene; E 7850; HMAF; Irofulven-1; LP 100; MGI 114

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of California, San Diego
  • Developer Dainippon Sumitomo Pharma; Eisai Co Ltd
  • Class Antineoplastics; Sesquiterpenes; Small molecules
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors; RNA polymerase II inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Renal cell carcinoma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Thyroid cancer

Most Recent Events

  • 31 Jan 2017 Oncology Venture plans to files a Clinical Trial Application in Denmark for Prostate cancer in the second quarter of 2017
  • 17 Jan 2017 Lantern Pharma enters into a strategic collaboration agreement with Cancer Genetics Incorporated
  • 30 Dec 2016 Irofulven licensed to 2X Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top